Schering-Plough's investigational sublingual Grass allergy immunotherapy tablet meets primary endpoint in phase III study
Friday, November 06, 2009 14:00 IST Kenilworth, New Jersey
Schering-Plough Corporation announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a phase-III